Explore the words cloud of the LeukoTheranostics project. It provides you a very rough idea of what is the project "LeukoTheranostics" about.
The following table provides information about the project.
Coordinator |
TEL AVIV UNIVERSITY
Organization address contact info |
Coordinator Country | Israel [IL] |
Project website | https://www3.tau.ac.il/danpeer/index.php/eu-project |
Total cost | 2˙703˙125 € |
EC max contribution | 2˙703˙125 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2014-CoG |
Funding Scheme | ERC-COG |
Starting year | 2015 |
Duration (year-month-day) | from 2015-11-01 to 2021-10-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | TEL AVIV UNIVERSITY | IL (TEL AVIV) | coordinator | 2˙527˙608.00 |
2 | CHILDREN'S HOSPITAL CORPORATION | US (BOSTON) | participant | 175˙517.00 |
'Inflammatory bowel diseases (IBD) is a group of chronic inflammatory conditions of the gastrointestinal tract, including Crohn’s disease (CD) and Ulcerative Colitis (UC) that can impact both the large and small bowel. IBD affects approximately 3.7 million Europeans and its peak onset is in persons of 15 to 30 years of age. IBD imposes a significant burden on Europe with over €3B in annual health care costs and over €3B in indirect cost. The prevalence of IBD is expected to increase by more than 40% over the next decade in many European countries. Therefore, to meet the needs of IBD patients in the European community, we must prepare for the evolving landscape of IBD care in the near future. Although its etiology remains unknown, unregulated immune cells are implicated in the pathogenesis of IBD. As many IBD patients are refractory to conventional medical treatments, there is an urgent need to develop novel therapeutic modalities in combination with real-time imaging in order to manage the disease. I will achieve this goal by generating a 'Trojan horse' strategy of targeting activated leukocytes that home to the gut in IBD rodent models and reprogram their fate using RNA interference (RNAi) combined with molecular imaging. The primary objective of this proposal is to reprogram in vivo activated leukocytes involved in gut inflammation using advanced RNAi-based therapeutics combined with molecular imaging strategies as the first theranostic modality utilizing leukocytes. The following specific aims include: (i) To develop and characterize unique integrin-targeted nanoparticles (I-tsNPs) targeting a high-affinity (HA) conformation of a4b7 integrin expressed on gut leukocytes; (ii) To study I-tsNPs 3-dimensional (3-D) delivery in colitis models using microPET/CT imaging; (iii) To investigate efficacy and safety profiles using the HA I-tsNPs platform for IBD therapeutics and disease management that will lay the foundation for future clinical trials. '
year | authors and title | journal | last update |
---|---|---|---|
2018 |
Ranit Kedmi, Nuphar Veiga, Srinivas Ramishetti, Meir Goldsmith, Daniel Rosenblum, Niels Dammes, Inbal Hazan-Halevy, Limor Nahary, Shani Leviatan-Ben-Arye, Michael Harlev, Mark Behlke, Itai Benhar, Judy Lieberman, Dan Peer A modular platform for targeted RNAi therapeutics published pages: 214-219, ISSN: 1748-3387, DOI: 10.1038/s41565-017-0043-5 |
Nature Nanotechnology 13/3 | 2020-02-21 |
2018 |
Daniel Rosenblum, Nitin Joshi, Wei Tao, Jeffrey M. Karp, Dan Peer Progress and challenges towards targeted delivery of cancer therapeutics published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-018-03705-y |
Nature Communications 9/1 | 2020-02-21 |
2018 |
Nuphar Veiga, Meir Goldsmith, Yasmin Granot, Daniel Rosenblum, Niels Dammes, Ranit Kedmi, Srinivas Ramishetti, Dan Peer Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-018-06936-1 |
Nature Communications 9/1 | 2020-02-21 |
2017 |
Shoshy Mizrahy, Inbal Hazan-Halevy, Niels Dammes, Dalit Landesman-Milo, Dan Peer Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes published pages: , ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2017.03.001 |
Molecular Therapy | 2020-02-21 |
2016 |
Inbal Hazan-Halevy, Dalit Landesman-Milo, Daniel Rosenblum, Shoshy Mizrahy, Brandon D. Ng, Dan Peer Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines published pages: 149-156, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2016.07.052 |
Journal of Controlled Release 244 | 2020-02-21 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEUKOTHERANOSTICS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LEUKOTHERANOSTICS" are provided by the European Opendata Portal: CORDIS opendata.